Cargando…

The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting

An extended‐release opioid analgesic (OxyContin, OC) was reformulated with abuse‐deterrent properties to deter abuse. This report examines changes in abuse through oral and nonoral routes, doctor‐shopping, and fatalities in 10 studies 3.5 years after reformulation. Changes in OC abuse from 1 year be...

Descripción completa

Detalles Bibliográficos
Autores principales: Coplan, PM, Chilcoat, HD, Butler, SF, Sellers, EM, Kadakia, A, Harikrishnan, V, Haddox, JD, Dart, RC
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102571/
https://www.ncbi.nlm.nih.gov/pubmed/27170195
http://dx.doi.org/10.1002/cpt.390
_version_ 1782466446108917760
author Coplan, PM
Chilcoat, HD
Butler, SF
Sellers, EM
Kadakia, A
Harikrishnan, V
Haddox, JD
Dart, RC
author_facet Coplan, PM
Chilcoat, HD
Butler, SF
Sellers, EM
Kadakia, A
Harikrishnan, V
Haddox, JD
Dart, RC
author_sort Coplan, PM
collection PubMed
description An extended‐release opioid analgesic (OxyContin, OC) was reformulated with abuse‐deterrent properties to deter abuse. This report examines changes in abuse through oral and nonoral routes, doctor‐shopping, and fatalities in 10 studies 3.5 years after reformulation. Changes in OC abuse from 1 year before to 3 years after OC reformulation were calculated, adjusted for prescription changes. Abuse of OC decreased 48% in national poison center surveillance systems, decreased 32% in a national drug treatment system, and decreased 27% among individuals prescribed OC in claims databases. Doctor‐shopping for OC decreased 50%. Overdose fatalities reported to the manufacturer decreased 65%. Abuse of other opioids without abuse‐deterrent properties decreased 2 years later than OC and with less magnitude, suggesting OC decreases were not due to broader opioid interventions. Consistent with the formulation, decreases were larger for nonoral than oral abuse. Abuse‐deterrent opioids may mitigate abuse and overdose risks among chronic pain patients.
format Online
Article
Text
id pubmed-5102571
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-51025712016-11-14 The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting Coplan, PM Chilcoat, HD Butler, SF Sellers, EM Kadakia, A Harikrishnan, V Haddox, JD Dart, RC Clin Pharmacol Ther Research An extended‐release opioid analgesic (OxyContin, OC) was reformulated with abuse‐deterrent properties to deter abuse. This report examines changes in abuse through oral and nonoral routes, doctor‐shopping, and fatalities in 10 studies 3.5 years after reformulation. Changes in OC abuse from 1 year before to 3 years after OC reformulation were calculated, adjusted for prescription changes. Abuse of OC decreased 48% in national poison center surveillance systems, decreased 32% in a national drug treatment system, and decreased 27% among individuals prescribed OC in claims databases. Doctor‐shopping for OC decreased 50%. Overdose fatalities reported to the manufacturer decreased 65%. Abuse of other opioids without abuse‐deterrent properties decreased 2 years later than OC and with less magnitude, suggesting OC decreases were not due to broader opioid interventions. Consistent with the formulation, decreases were larger for nonoral than oral abuse. Abuse‐deterrent opioids may mitigate abuse and overdose risks among chronic pain patients. John Wiley and Sons Inc. 2016-06-22 2016-09 /pmc/articles/PMC5102571/ /pubmed/27170195 http://dx.doi.org/10.1002/cpt.390 Text en © 2016 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of The American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research
Coplan, PM
Chilcoat, HD
Butler, SF
Sellers, EM
Kadakia, A
Harikrishnan, V
Haddox, JD
Dart, RC
The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
title The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
title_full The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
title_fullStr The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
title_full_unstemmed The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
title_short The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
title_sort effect of an abuse‐deterrent opioid formulation (oxycontin) on opioid abuse‐related outcomes in the postmarketing setting
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102571/
https://www.ncbi.nlm.nih.gov/pubmed/27170195
http://dx.doi.org/10.1002/cpt.390
work_keys_str_mv AT coplanpm theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT chilcoathd theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT butlersf theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT sellersem theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT kadakiaa theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT harikrishnanv theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT haddoxjd theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT dartrc theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT coplanpm effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT chilcoathd effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT butlersf effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT sellersem effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT kadakiaa effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT harikrishnanv effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT haddoxjd effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting
AT dartrc effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting